verified SJR 1,018 · Q2 • database Scopus / SJR & Web of Science indexed

Netherlands · Springer Science and Busines...

workspace_premium Q2 — Genetics lock Subscription

Familial Cancer

Familial Cancer is a journal indexed in SJR in Genetics and Oncology with an H index of 70. It has a price of 3190 €. It has an SJR impact factor of 1,018 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 1,018.

Familial Cancer focuses its scope in these topics and keywords: cancer, aspiration, risk, breast, women, increased, nipple, oxytocinassisted, middle, cancerlowlevel, ...

ISSN: 1389-9600

Publisher: Springer Science and Business Media B.V.

Category: Genetics

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,018 Q2

H-index 70

Acceptance rate pie_chart

28% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.190 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,018

H-index

Docs (year)

Docs 3y

148

Total refs

2783

Cites 3y

329

Citable 3y

138

Cites/Doc 2y

1.99

Ref/Doc

40.33

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge

Identification of a novel MSH6 germline variant in a family with multiple gastro-intestinal malignancies by next generation sequencing

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma

Predictors of choosing life-long screening or prophylactic surgery in women at high and moderate risk for breast and ovarian cancer

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer

The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer

Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations

Tumor histology helps to identify Lynch syndrome among colorectal cancer patients

Two novel mutations in hMLH1 gene in Iranian hereditary non-polyposis colorectal cancer patients

Vestibular schwannoma in a patient with neurofibromatosis type 1: clinical report and literature review

What motivates interest in attending a familial cancer genetics clinic?

The effect of oral 3,3'-diindolylmethane supplementation on the 2:16a-OHE ratio in BRCA1 mutation carriers

SHOW MORE ARTICLES

Predictive genetic testing in a young child: a case report

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations

Non-truncating hMLH1 variants identified in Slovenian gastric cancer patients are not associated with Lynch Syndrome: a functional analysis report

Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy

Nevoid basal cell carcinoma syndrome caused by splicing mutations in the PTCH1 gene

Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma

Low Prevalence of BRCA1 Exon Rearrangements in Familial and Young Sporadic Breast Cancer Patients

Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population

Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer

Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome)

Impact of computer-assisted data collection, evaluation and management on the cancer genetic counselor's time providing patient care

IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer

FAQs

Familial Cancer has an SJR of 1,018 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is 3190 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Familial Cancer is 28%.

Familial Cancer

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Familial Cancer?

What is the APC / publication cost?

What is the acceptance rate?